
|Articles|July 1, 2002
Anti-VEGF therapy holds promise for CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
2
New optoretinography technique allows direct measurement of rod function in vivo
3
Long-lived Greenland sharks may point to new approaches for retinal disease
4
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
5












































